Abstract
The emergent epidemic of metabolic syndrome and its complex list of sequelae mandate a more thorough understanding of benign prostatic hyperplasia and lower urinary tract symptoms (BPH/LUTS) in the context of systemic metabolic disease. Here we discuss the nature and origins of BPH, examine its role as a component of LUTS and review retrospective clinical studies that have drawn associations between BPH/LUTS and type II diabetes, inflammation and dyslipidemia. PPARγ signaling, which sits at the nexus of systemic metabolic disease and BPH/LUTS through its regulation of inflammation and insulin resistance, is proposed as a candidate for molecular manipulation in regard to BPH/LUTS. Finally, we introduce new cell and animal models that are being used to study the consequences of obesity, diabetes and inflammation on benign prostatic growth.
Original language | English (US) |
---|---|
Pages (from-to) | 220-236 |
Number of pages | 17 |
Journal | Differentiation |
Volume | 82 |
Issue number | 4-5 |
DOIs | |
State | Published - Nov 2011 |
Keywords
- BPH
- Co-morbidities
- Inflammation
- LUTS
- Metabolism
- PPARγ
ASJC Scopus subject areas
- Molecular Biology
- Developmental Biology
- Cell Biology
- Cancer Research